Company Overview and News
Larger and more financially healthy E&P companies are grouped together for analysis purposes in this "Tier One Producer" or "TOP Club"
CRC GDPMQ CHKVP PSX CRK QEP CHKVZ CRZO GDAOQ EGC EXXIQ SNZYP GDRRQ AMPY TALO SRCI EEXXQ BCEI RRS JONE WPX ESTE EXXI GDP CHK SGY TTEN MPOYQ SDRXP LINE SDRXQ APA HES DVN PVA EPE PIONF CHKDH CHKDG MCF CHKDJ ROSEU VNR CHKDP REI RSPP JNEEP AMR AMGP JAG ROSE LINEQ CKRGZ EVEP EOG RGRYY UPLMQ VNRCP PIO LNGG AR SWTF AM EXIXQ CHAP VNRBP SN XOG NBL WLL PDCE SM CTLR HKRCP SD RGRLF RRC DNR MPO VNRAP CLR GDPAN GDPAQ ECR CHPE UPL WPXP SDRPQ REN PE CXO RRL SCAZP AXAS COP AREX ECA SFY EVEPQ CDEV BRMR GDPM PVAYQ VNRR ECA SBOW CHKWZ GDUEQ SDOCQ GDANQ CHK.WI PVAC LPI WES HK HPR BRY
For years trusts like BPT have offered exposure to rising commodity prices in a high-yield vehicle; however, many publicly traded trusts are nearing the end of their finite lifespans.
PIO XOM LNGG CHKVP CXO PIONF CHKDH CHKVZ XTO CHKDG CHKDJ VNR CHKDP VNRBP LINEQ CKRGZ NBL BSM VNRR CHKWZ BPT CHK.WI CHK VNRAP VNRCP LINE
2018-09-24 seekingalpha - 4
Gastar Exploration recently hired investment bankers to pursue the sale of the company after its primary creditor, Ares, essentially forced the issue.
LINEQ CAMZF CAMZD GST-A LNGG CTLR GST-B DVN GST NFX EOG SPAQ CHAP MRO CLR LINE
HOUSTON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTCQB: LNGG) (“LINN” or the “Company”) announces that is has posted on its website IRS Form 8937 regarding the estimated federal income tax characteristics of its spin-off of Riviera Resources, Inc. (“Riviera”) from LINN (the “Spin-Off”) that was completed on August 7, 2018.
LINEQ RVRA LNGG LINE
HOUSTON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTCQB: LNGG) (“LINN” or the “Company”) today announced that it has entered into a master reorganization agreement (the “Reorganization Agreement”) with Roan Holdings, LLC (“Roan Holdings”) and Roan Resources LLC (“Roan LLC”), to effectuate the reorganization of LINN’s and Roan Holdings’ respective 50% equity interests in Roan LLC under a newly formed company, Roan Resources, Inc.
LINEQ LNGG DTK LINE
2018-09-17 seekingalpha - 3
They're baaack! Actually, some of them have been back for a while, but I have not felt compelled to write about them until now. "They" are, of course, former members of my Bottom of the Barrel Club who declared bankruptcy during the past 2-3 years. The companies in this article are now trading publicly again (with 1 or 2 exceptions). I may refer to them as the "X-11 Club" occasionally.
ECR CHPE UPL GDPMQ LNGG SDRPQ DVN PVA GDAOQ VNR CHAP VNRBP GDRRQ LINEQ TALO GDPM BRMR PVAYQ VNRR HKRCP SBOW SD GDUEQ SDOCQ GDANQ GDP RVRA PVAC SGY HK MPO VNRAP TTEN MPOYQ VNRCP UPLMQ BRY GDPAN SDRXP LINE SDRXQ GDPAQ
If Abraxas can maintain drilling inventory and production levels with a $110 million capital expenditure budget in 2019, then it is projected to have $19 million in positive cash flow.
LINEQ LNGG AXAS LINE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET